InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (1 ops.)
Insider track record
Board DirectorDisclosed buys
1
Disclosed sells
1
T+90 hit rate
0%
T+90 mean return
-33.9%
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Jan HOFLACK, Director. Officer active across 2 companies, notably Oncodesign Precision Medicine S.A.. Aggregated, 2 filings have been recorded. Split: 1 buy · 1 sell. Total volume traded: €5.3m. Activity tracked since 18 October 2022. The latest transaction was disclosed on 8 December 2022 (Acquisition). Regulator: AMF. The full history is free.
Declarations2 total
150,000 shares@ €0.82100.0% of flowActionHors plateforme de négociation2022DD876585
Ideal exit: 4 Sept 2023 (T+270)
357,840 shares@ €14.42100.0% of flowActionHors plateforme de négociation2022DD867440
2 of 2 declarations
About Jan HOFLACK
Jan Hoflack is a Board Member of ONCODESIGN PRECISION MEDICINE S.A. and ONCODESIGN. He contributes to the governance of the companies and strategic decision-making, bringing his expertise in biotechnology and business development.
